Details of the Drug | DrugMAP

General Information of Drug (ID: DMWW1YB)

Drug Name

Oratecan

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]
------------------------------------------------------------------------------------

Structure

3D MOL is unavailable

2D MOL

Chemical Identifiers

Formula: C33H39ClN4O6
Canonical SMILES: CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl
InChI: 1S/C33H38N4O6.ClH/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2;/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3;1H/t33-;/m1./s1
InChIKey: GURKHSYORGJETM-MGDILKBHSA-N

Cross-matching ID

PubChem CID: 91654792
TTD ID: D0P5AA

References

1	ClinicalTrials.gov (NCT02250157) A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies. U.S. National Institutes of Health.